1. Home
  2. PRLD vs JUNE Comparison

PRLD vs JUNE Comparison

Compare PRLD & JUNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • JUNE
  • Stock Information
  • Founded
  • PRLD 2016
  • JUNE 1998
  • Country
  • PRLD United States
  • JUNE Singapore
  • Employees
  • PRLD N/A
  • JUNE N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • JUNE
  • Sector
  • PRLD Health Care
  • JUNE
  • Exchange
  • PRLD Nasdaq
  • JUNE Nasdaq
  • Market Cap
  • PRLD 73.7M
  • JUNE 83.2M
  • IPO Year
  • PRLD 2020
  • JUNE 2024
  • Fundamental
  • Price
  • PRLD $0.81
  • JUNE $11.11
  • Analyst Decision
  • PRLD Strong Buy
  • JUNE
  • Analyst Count
  • PRLD 2
  • JUNE 0
  • Target Price
  • PRLD $4.50
  • JUNE N/A
  • AVG Volume (30 Days)
  • PRLD 279.1K
  • JUNE 107.7K
  • Earning Date
  • PRLD 05-06-2025
  • JUNE 05-10-2025
  • Dividend Yield
  • PRLD N/A
  • JUNE N/A
  • EPS Growth
  • PRLD N/A
  • JUNE N/A
  • EPS
  • PRLD N/A
  • JUNE N/A
  • Revenue
  • PRLD $7,000,000.00
  • JUNE $2,903,179.00
  • Revenue This Year
  • PRLD N/A
  • JUNE N/A
  • Revenue Next Year
  • PRLD N/A
  • JUNE N/A
  • P/E Ratio
  • PRLD N/A
  • JUNE N/A
  • Revenue Growth
  • PRLD N/A
  • JUNE N/A
  • 52 Week Low
  • PRLD $0.61
  • JUNE $2.75
  • 52 Week High
  • PRLD $6.80
  • JUNE $12.50
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 57.52
  • JUNE N/A
  • Support Level
  • PRLD $0.71
  • JUNE N/A
  • Resistance Level
  • PRLD $0.72
  • JUNE N/A
  • Average True Range (ATR)
  • PRLD 0.08
  • JUNE 0.00
  • MACD
  • PRLD 0.02
  • JUNE 0.00
  • Stochastic Oscillator
  • PRLD 76.92
  • JUNE 0.00

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About JUNE Junee Limited Ordinary Shares

Junee Ltd is a holding company that operates through its subsidiary. It is engaged in providing design, fit-out, repair, and maintenance services for commercial and residential buildings. The design services include both the consultation with its staff and the actual design work. Fit-out works include installing protective materials to cover floors or walls, installing or constructing partition walls, installing switches, power outlets, telephone wiring, computer outlet covers, and other electrical and wiring works. Repair and maintenance works include, among other things, replacement of fixtures and fittings, repair and maintenance of cupboards and shelves, and repainting walls and ceilings. Geographically, the company derives all of its revenue from its customers in Hong Kong.

Share on Social Networks: